Halozyme Therapeutics (HALO)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Drug Deliverysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 12.92% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Merck’s Keytruda Is Dealt a Legal Setback. It’s Good News for This Biotech Stock.
- Sector Update: Healthcare Stocks Rise in Afternoon Trading
- Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks
- Halozyme Announces Appointment of Jim Daly to its Board of Directors
- Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?
- Halozyme (HALO) Just Made A $1.3B Bet On Itself
- Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost?
- Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Halozyme Therapeutics.
Full HALO Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.